RE:MSL Q3 Conference Callthis need to be repeated now that we have bashing aholes on board.
lscfa wrote: - when switch from Novartis to European manufacturers is soon done currency impacts disappear (e.g. revenues in euros, costs in euros)
- guidance increased on Sintrom manufacturing savings to $8 million/yr from $5 million/yr
- currently in active discussions for 12 acquisition products with combined $150 million ebitda.
- size range of potential acquisitions is $2 million to $60 million in revenue
- price range of potential acquisitions is still 4x to 6x ebitda
- several of the potential acquisition targets are drugs for US territory (tax inversion scheme?)